Breast Cancers Today

Breast Cancers Today features breaking news, commentary, expert interviews, and more updates to inform healthcare professionals on the latest research and best clinical practices in the breast cancer space.

HER2

TNBC

Genetics

ASCO 2025: Breast Cancers Today

Explore key insights, expert perspectives, and practice-changing research in breast cancer presented at the 2025 ASCO Annual Meeting.

Latest News

Treating Brain and Leptomeningeal Metastases: Promising TUXEDO-3 Data with HER3-Directed ADC

Rupert Bartsch, MDHER2 Breast Cancer | June 5, 2025

HER3-DXd shows promise for CNS metastases in breast and lung cancer in the TUXEDO-3 trial, including patients with LMD.

Interpreting ASCENT-04 Findings With Dr. Sarah Tolaney

Sara Tolaney, MD, MPHTriple-Negative Breast Cancer | June 5, 2025

Sacituzumab + pembrolizumab improved PFS vs chemo in PD-L1+ TNBC in ASCENT-04, with no new safety signals.

Dr. Erika Hamilton on VERITAC-2: Vepdegestrant Shows PFS Benefit in ESR1m ER+/HER2- Breast Cancer

Erika P. Hamilton, MDHR Breast Cancer | June 5, 2025

Vepdegestrant improves PFS in ESR1-mutant ER+/HER2- breast cancer, offering a well-tolerated oral option post-CDK4/6.

ASCENT-04/KEYNOTE-D19 Supports Sacituzumab Govitecan Plus Pembrolizumab As New Standard of Care in Advanced PD-L1–Positive TNBC

Lauren Dembeck, PhDTriple-Negative Breast Cancer | June 4, 2025

Sacituzumab + pembrolizumab improves PFS vs chemo in PD-L1+ TNBC, per ASCENT-04/KEYNOTE-D19 phase 3 trial at ASCO 2025.

DESTINY-Breast09: Will T-DXd + Pertuzumab Replace THP in First-Line HER2+ mBC?

Maryam Lustberg, MD, MPHHER2 Breast Cancer | June 4, 2025

Dr. Lustberg discusses DESTINY-Breast09 and the potential shift to T-DXd + pertuzumab in HER2+ mBC first-line treatment.

Dr. Stephanie Graff’s Top 3 Breast Cancer Abstracts from ASCO 2025

Stephanie L. Graff, MDHER2 Breast Cancer | June 4, 2025

Stephanie Graff, MD, reviews top ASCO25 breast cancer trials, including ASCENT-04, DESTINY-Breast09, and SERENA-6.

Dr. Gradishar on Managing Toxicities and Tailoring Treatment in HER2+ mBC

William J. Gradishar, MDHER2 Breast Cancer | June 5, 2025

Dr. Gradishar discusses how tolerability, toxicity, and NCCN guidelines shape HER2+ breast cancer treatment decisions.

Sequencing HER2-Targeted Therapies: What Comes After THP?

William J. Gradishar, MDHER2 Breast Cancer | June 5, 2025

Dr. William Gradishar discusses treatment sequencing strategies for HER2+ metastatic breast cancer at ASCO 2025.

DESTINY-Breast09: T-DXd Plus Pertuzumab Boosts PFS in HER2+ mBC

Yvette C. TerrieHER2 Breast Cancer | June 3, 2025

T-DXd plus pertuzumab significantly improves PFS vs THP in HER2+ mBC, per interim results from DESTINY-Breast09.

Elinzanetant Eases Vasomotor Symptoms in HR+ Breast Cancer

Lauren Dembeck, PhDHR Breast Cancer | June 3, 2025

Elinzanetant reduces vasomotor symptoms from endocrine therapy in HR+ breast cancer, with rapid onset and good tolerability.

Expert Interviews

Editorial Board

Stephanie L. Graff, MDEditor | Director of Breast Oncology, Brown University Health Cancer Institute

Rebecca Shatsky, MDEditor | Associate Professor of Medicine, Moores Cancer Center at the University of California, San Diego

Maryam Lustberg, MD, MPHEditor | Director of the Center for Breast Cancer, Smilow Cancer Hospital and Yale Cancer Center

Erika P. Hamilton, MDEditor | Director of Breast Cancer and Gynecologic Cancer Research, Sarah Cannon Research Institute

Sarah Sammons, MDEditor | Associate Director, Metastatic Breast Cancer Program, Dana-Farber Cancer Institute